https://pmc.ncbi.nlm.nih.gov/articles/PMC12203001/
Eravacycline as a last resort for difficult-to-treat resistant Acinetobacter baumannii infections...
To describe eravacycline use as a salvage treatment for ventilator-associated pneumonia (VAP) caused by difficult-to-treat resistant (DTR) Acinetobacter...
https://pmc.ncbi.nlm.nih.gov/articles/PMC11370244/
Emergence of plasmid-borne tet(X4) resistance gene in clinical isolate of eravacycline- and...
Omadacycline and eravacycline are gradually being used as new tetracycline antibiotics for the clinical treatment of Gram-negative pathogens. Affected by...
https://pmc.ncbi.nlm.nih.gov/articles/PMC4325809/
Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including...
Eravacycline demonstrated in vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with...
acinetobacter baumanniiactivityeravacyclineenterobacteriaceaeincluding
https://pmc.ncbi.nlm.nih.gov/articles/PMC7038303/
In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories...
Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by...
gram negative bacilliin vitro
https://pmc.ncbi.nlm.nih.gov/articles/PMC6735687/
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs...
Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials....
phase 3
https://pmc.ncbi.nlm.nih.gov/articles/PMC5923129/
Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical...
The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant...